scholarly journals Mandatory pharmacist-led education session for patients seeking medical cannabis

2020 ◽  
Vol 18 (4) ◽  
pp. 2088
Author(s):  
Vikas Parihar ◽  
Laura Katz ◽  
Mahmoud A. Siyam ◽  
Anna Rogers ◽  
Lisa Patterson ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Perceived Benefits ◽  
Medical Cannabis ◽  
Education Session ◽  
Chi Square ◽  
Mandatory Education ◽  
Chronic Pain Patients ◽  
The Future ◽  
The Impact ◽  
Pain Patients

Objective: The primary objectives of this pre-post session study, was to evaluate the impact of a pharmacist-led education session on the perceived benefits and safety of cannabis among patients with chronic pain, as well as determine the influence of pharmacist education on the selection of safer cannabis products and dosage forms for medical use among patients. Methods: A retrospective analysis of completed pre-post session questionnaires was conducted among chronic pain patients attending a mandatory education session led by a pharmacist, prior to being authorized cannabis in clinic. All questionnaire data was analyzed using SPSS v. 25. Demographic and sample characteristics were reviewed using univariate analyses. Chi-Square tests were employed to determine if the group-based education significantly affected knowledge, perception of efficacy and safety of cannabis. Results: Of the 260 session participants, 203 completed pre-post session questionnaires. After the session, a majority of current cannabis users (33.8%) and cannabis naïve/past users (56.9%) reported they would use a low THC product in the future, and a majority of current users (54.5%) would use a high CBD product in the future. After education, participants were more likely to report cannabis as having the potential for addiction (chi-square =42.6, p <0.0001) and harm (chi-square =34.0, p <0.0001). Conclusions: Pharmacist counselling and education has the potential to influence patient selection and use of cannabis, from more harmful to safer products, as well as moderate the potential perceived benefits of use.

Longitudinal trial of a smartphone pain application for chronic pain patients: Predictors of compliance and satisfaction

2016 ◽  
Vol 24 (2) ◽  
pp. 93-100 ◽  
Author(s):  
Robert N Jamison ◽  
Anna Mei ◽  
Edgar L Ross
Keyword(s):  
Chronic Pain ◽  
Future Development ◽  
Activity Monitor ◽  
Safety And Efficacy ◽  
Safety Issues ◽  
Frequent Use ◽  
Chronic Pain Patients ◽  
The Future ◽  
Pain Patients ◽  
Positive Effect

Introduction This study was designed to determine the feasibility, tolerability, safety and efficacy of a smartphone pain application (app) among chronic pain patients over a six-month trial. The app was designed for both Android and iPhone devices and enabled users with chronic pain to assess, monitor, and communicate their status to their providers. Methods We recruited 90 chronic pain patients to use the pain app. All subjects completed baseline measures and were asked to record their progress every day. All participants were supplied an activity monitor. Results Average age of the participants was 46.7 years (range 18–79), 64.4% were female and 31.1% reported multiple pain sites. Satisfaction was rated at three and six months. The app was found to be easily introduced and well tolerated. In general, those who used the app more often were more satisfied with the program ( p < 0.05), although satisfaction ratings of the pain app diminished with time. Greater use of the app and frequent daily assessment entries were found to be related to an overall improvement in mood. However, contrary to our hypotheses, frequent use of the app did not have a positive effect on pain or activity. Those who were more satisfied with the app reported more pain-related disability and were less active than those who were less satisfied with the app. No safety issues were encountered. Discussion Strategies to make the program more engaging and to improve motivation to use the app would be important in the future development and use of a smartphone pain app.

The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use

2015 ◽  
Vol 69 (12) ◽  
pp. 1448-1456 ◽  
Author(s):  
R. J. LoCasale ◽  
C. J. Datto ◽  
M. K. Margolis ◽  
J. Tack ◽  
K. S. Coyne
Keyword(s):  
Chronic Pain ◽  
Laxative Use ◽  
Chronic Pain Patients ◽  
The Impact ◽  
Pain Patients

The impact of structural therapy on functioning and pain in chronic pain patients: A pilot study1

2007 ◽  
Vol 20 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Alice V. Fann ◽  
H.J. Spencer ◽  
Amelia F. Hammaker ◽  
Svetlana Kligman ◽  
Richard P. Gray
Keyword(s):  
Chronic Pain ◽  
Chronic Pain Patients ◽  
Structural Therapy ◽  
The Impact ◽  
Pain Patients

scholarly journals The Anxiety and Pain of Fibromyalgia Patients during the COVID-19 Pandemic

2020 ◽  
Author(s):  
A. Y. Kharko ◽  
K. J. Hansford ◽  
P. L. Furlong ◽  
S. D. Hall ◽  
M. E. Roser
Keyword(s):  
Chronic Pain ◽  
Online Survey ◽  
Mixed Effects ◽  
Caffeine Intake ◽  
Health Decline ◽  
Chronic Pain Patients ◽  
The Impact ◽  
Pain Patients ◽  
Mild Analgesics

AbstractBackgroundEarly research on the impact of the COVID-19 pandemic found persistent related anxiety in the general population. We hypothesised that this anxiety will be associated with increased pain in chronic pain patients diagnosed with fibromyalgia (FM).MethodsTo study this, we carried out a 10-day online survey with 58 female participants, diagnosed with FM and no other pain condition. We identified which aspects of the COVID-19 pandemic evoked anxiety. We then asked participants to provide daily ratings of both anxiety and pain on 101-point visual analogue scales (VAS). Key participant characteristics were included as mediators in a mixed-effects analysis, where the primary outcome was pain VAS.ResultsWe found that participants were most often anxious about “impact on relationships”, “a family member contracting COVID-19”, and “financial hardships”, but on average rated “financial hardship”, “access to medication”, and “home loss/eviction” as evoking the strongest anxiety. Mixed-effects modelling showed that an increase in pain was significantly associated with an increase in anxiety, when taking into account individual variance and daily caffeine intake. Age and intake of some mild analgesics were also linked to stronger pain.ConclusionOur results extend the initial findings from the literature about the effects of COVID-19 pandemic on chronic pain sufferers. We found that not only is pandemic anxiety in FM patients present, but it is associated with amplified self-assessed chronic pain.SignificanceThe long-term support of fibromyalgia patients is challenging for healthcare professionals due to the nature of the condition. The new normal introduced by the pandemic particularly hinders pain management, which is the leading request from this patient group. Our study demonstrates that mental health decline during the COVID-19 pandemic is directly related to the worsening of pain in fibromyalgia. Core stressors that evoke the strongest anxiety were identified thus providing guidance for where to focus patient support.

Temporal summation in chronic pain patients: the impact of catastrophizing, distraction analgesia and opioid use

2013 ◽  
Vol 14 (4) ◽  
pp. S54
Author(s):  
K. Schreiber ◽  
C. Campbell ◽  
C. Cahalan ◽  
G. Mensing ◽  
R. Edwards
Keyword(s):  
Chronic Pain ◽  
Temporal Summation ◽  
Opioid Use ◽  
Chronic Pain Patients ◽  
The Impact ◽  
Pain Patients

The Impact of Chronic Pain Patients' Psychotropic Drug Knowledge and Warning Labels on the Decision Whether to Drive a Car or Not

2006 ◽  
Vol 7 (4) ◽  
pp. 360-364 ◽  
Author(s):  
D. S. Veldhuijzen ◽  
A. J. M. van Wijck ◽  
J. C. Verster ◽  
C. J. Kalkman ◽  
J. L. Kenemans ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Psychotropic Drug ◽  
Warning Labels ◽  
Chronic Pain Patients ◽  
Drug Knowledge ◽  
The Impact ◽  
Pain Patients

Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study

Pain Medicine ◽  
2020 ◽  
Vol 21 (11) ◽  
pp. 3073-3086 ◽  
Author(s):  
Ramin Safakish ◽  
Gordon Ko ◽  
Vahid Salimpour ◽  
Bryan Hendin ◽  
Imrat Sohanpal ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Observational Study ◽  
Medication Use ◽  
Medical Cannabis ◽  
Opioid Medication ◽  
Chronic Pain Patients ◽  
Pain Patients ◽  
Observation Period

Abstract Objective To evaluate the short-term and long-term effects of plant-based medical cannabis in a chronic pain population over the course of one year. Design A longitudinal, prospective, 12-month observational study. Setting Patients were recruited and treated at a clinic specializing in medical cannabis care from October 2015 to March 2019. Subjects A total of 751 chronic pain patients initiating medical cannabis treatment. Methods Study participants completed the Brief Pain Inventory and the 12-item Short Form Survey (SF-12), as well as surveys on opioid medication use and adverse events, at baseline and once a month for 12 months. Results Medical cannabis treatment was associated with improvements in pain severity and interference (P &lt; 0.001) observed at one month and maintained over the 12-month observation period. Significant improvements were also observed in the SF-12 physical and mental health domains (P &lt; 0.002) starting at three months. Significant decreases in headaches, fatigue, anxiety, and nausea were observed after initiation of treatment (P ≤ 0.002). In patients who reported opioid medication use at baseline, there were significant reductions in oral morphine equivalent doses (P &lt; 0.0001), while correlates of pain were significantly improved by the end of the study observation period. Conclusions Taken together, the findings of this study add to the cumulative evidence in support of plant-based medical cannabis as a safe and effective treatment option and potential opioid medication substitute or augmentation therapy for the management of symptoms and quality of life in chronic pain patients.

Sign in / Sign up

Export Citation Format

Share Document